FDA.reportPublic FDA data

Esperoct 1 UNT Injection

RxCUI
2275729
RxNorm name
Esperoct 1 UNT Injection
Display name
Esperoct 1 UNT Injection
Full name
Esperoct 1 UNT Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:59

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125671EsperoctAntihemophilic Factor (Recombinant), GlycoPEGylated-exei351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
562f94e8-825f-4d7f-b93c-b783ac3a43bcEsperoct 1 UNT InjectionSY7These highlights do not include all the information needed to use ESPEROCT ® safely and effectively. See full prescribing information for ESPEROCT. ESPEROCT [antihemophilic factor (recombinant), glycopegylated-exei] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 201920240701
562f94e8-825f-4d7f-b93c-b783ac3a43bcantihemophilic factor (recombinant) pegylated-exei 1 UNT Injection [Esperoct]SBD7These highlights do not include all the information needed to use ESPEROCT ® safely and effectively. See full prescribing information for ESPEROCT. ESPEROCT [antihemophilic factor (recombinant), glycopegylated-exei] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 201920240701
562f94e8-825f-4d7f-b93c-b783ac3a43bcESPEROCT 1 UNT InjectionPSN7These highlights do not include all the information needed to use ESPEROCT ® safely and effectively. See full prescribing information for ESPEROCT. ESPEROCT [antihemophilic factor (recombinant), glycopegylated-exei] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 201920240701